IDH-mutant glioma: A new IDH1 inhibitor moves forward

Affiliations

Editorial

Julie J Miller et al. Neuro Oncol. 2023.

. 2023 Feb 14;25(2):337-338.

doi: 10.1093/neuonc/noac275.

¹ Stephen E. and Catherine Pappas Center for Neuro-Oncology Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

No abstract available

Comment on

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K, Mineharu Y, Miyakita Y, Yamasaki F, Matsushita Y, Ichimura K, Ito K, Tachibana M, Kakurai Y, Okamoto N, Asahi T, Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura H, Nishikawa R. Natsume A, et al. Neuro Oncol. 2023 Feb 14;25(2):326-336. doi: 10.1093/neuonc/noac155. Neuro Oncol. 2023. PMID: 35722822 Free PMC article. Clinical Trial.

1. Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018;34(2):186–195. - PMC - PubMed
1. Mellinghoff IK, Ellingson BM, Touat M, et al. . Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398–3406. - PMC - PubMed
1. Mellinghoff IK, Penas-Prado M, Peters KB, et al. . Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res. 2021;27(16):4491–4499. - PMC - PubMed
1. Natsume A, Arakawa Y, Narita Y, et al. . The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2023;25(2):326–336. - PMC - PubMed